Metabolomics Market Outlook 2031
The global metabolomics market size was USD 2.56 Billion in 2022 and is estimated to reach USD 7.21 Billion by 2031, expanding at a CAGR of 12.2% during the forecast period, 2023–2031. The growth of the market is attributed to the increasing R&D expenditure in the biopharmaceuticals & pharmaceutical industry, rising investment of government and private institution on metabolomics research, and ongoing improvements in metabolomics instruments.
Scientifically, metabolomics is the study of specific chemical processes within cells that include metabolites. Furthermore, metabolites refers to all of the metabolites found in a biological cell, organ, and tissue collectively, which are the end products of cellular processes.
Moreover, metabolomics is a relatively new field that encompasses the measurement of all metabolites and low-molecular-weight compounds in a biological material. Furthermore, it provides for the profiling of a far higher number of metabolites than traditional clinical laboratory techniques.
As a result of its comprehensive coverage of biological processes and metabolic pathways, it continues to be a fundamental objective lens for precision medicine in molecular microscopes.
However, metabolites are closely related to an organism's phenotype and can be utilized for a variety of purposes including phenotyping genetically altered plants, identifying gene function, studying biotic-abiotic stress reactions, and significant equivalence testing. Furthermore, it aids researchers and scientists in calculating physiological effects and observing the negative effects of medications on an organism.
The COVID-19 pandemic has severely impacted on the life science instruments market. The manufacturing and supply chain related challenges affected the analytical instruments industry such as getting products to end users on time and meeting inconsistent demand for products and services for few months.
Metabolomics Market Trends, Drivers, Restraints, and Opportunities
- Increasing geriatric population globally as well as rising cases of diabetes and cancer are some of the key factors propelling the market growth.
- Growing adoption rate of metabolomics as a R&D tool and increasing usage of metabolomics as drug discovery tool by key pharmaceutical companies are fueling the market expansion.
- Increasing patient awareness levels and cost effective toxicological studies on investigational drugs are some other key drivers of the market.
- High data complexity generated during life science research and difficulty in effective data points evaluation are key restraining factors that can hinder the growth of the metabolomics market.
- Technological advancement in metabolomics to identify new biomarkers related to sensitivity, safety, and resistance to commercially available drugs is expected to offer tremendous opportunity for market growth in the coming years.
Scope of Metabolomics Market Report
The report on the global metabolomics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Metabolomics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Applications (Toxicology, Biomarker & Drug Discovery, Personalized Medicine, Nutrigenomics, and Others) and Production Technology (Liquid Chromatography, Mass Spectrometry, Nuclear Magnetic Resonance Spectroscopy, Gas Chromatography, Capillary Electrophoresis, and Others)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
Human Metabolome Technologies; Phenomenome Discoveries Inc.; Bruker Corp.; Metabolon, Inc.; and Agilent Technologies.
Metabolomics Market Segment Insights
Applications Segment Analysis
Based on applications, the global metabolomics market is segmented into toxicology, biomarker & drug discovery, personalized medicine, nutrigenomics, and others. The biomarker & drug discovery segment is expected to grow at a rapid pace during the forecast period, due to the growing challenges faced by the pharmaceutical industry such as declining discovery pipelines, less budget endorsed for a particular R&D, rising regulatory control, and significant gaps in the future drug markets.
Moreover, the objective and quantitatively observable signs of biological or pathological processes are known as biomarkers. Both metabolomics and biomarkers are increasingly being employed in medication research and disorder management, particularly for personalized medicine.
In addition, metabolomics and biomarkers are likely to promote drug discovery and tailored therapy, particularly in high-demand disease areas, such as cancer, cardiovascular & metabolic diseases, mental health, and other infectious diseases. Thus, all these factors are expected to boost the segment growth.
Production Technology Segment Analysis
On the basis of production technology, the market is segregated as liquid chromatography, mass spectrometry, nuclear magnetic resonance spectroscopy, gas chromatography, capillary electrophoresis, and others.
The gas chromatography (GC) segment is projected to expand at a considerable CAGR during the forecast period owing to the advanced technology in analytical instruments such as miniaturization, automation, and computerization, growing number of R&D activities in the field of medicine, nutraceuticals, and metabolomics, and well established healthcare infrastructure in emerging economies for efficient disease diagnosis and treatment.
Moreover, the National Institute of Health Sciences (NIHS) in Japan has approved the use of gas chromatography and liquid chromatography and gas chromatography for drug testing, particularly in determining the purity and efficacy of new pharmacological analyses.
Furthermore, high usage of gas chromatography in medication approvals and growing government support in the form of subsidies are estimated to boost the segment growth.
In terms of regions, the global metabolomics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the forecast period.
The regional market growth is attributed to the presence of key pharmaceutical companies operating in the metabolomics market and increasing biomedical research especially in the US and ongoing preclinical activities by contract research organizations (CROs) in the region.
However, the Asia Pacific market is projected to register a substantial CAGR during the forecast period. The growth of the market in the region is attributed to the increasing demand for enhanced pharmaceutical products from developing economies such as India and China, and the encouraging government policies to support new product development by key players.
The global metabolomics market has been segmented on the basis of
- Biomarker & Drug Discovery
- Personalized Medicine
- Liquid Chromatography
- Mass Spectrometry
- Nuclear Magnetic Resonance Spectroscopy
- Gas Chromatography
- Capillary Electrophoresis
- Asia Pacific
- North America
- Latin America
- Middle East & Africa
Some of the key players competing in the global metabolomics market are Human Metabolome Technologies; Phenomenome Discoveries Inc.; Bruker Corp.; Metabolon, Inc.; and Agilent Technologies. These major players are implementing various marketing strategies such as capital investments, merger & acquisitions, and new product development to enhance their market position in the regional as well as global competition.
Moreover, high performance liquid chromatography (HPLC) and ultra performance liquid chromatography (UPLC) are increasingly preferred over other techniques for their most adaptable separation method in metabolite research due to the unique requirements.
To characterize toxicological investigations and develop novel medications against infectious diseases, several pharmaceutical firms prefer research centers. Furthermore, technical developments as well as their integration with multiple sclerosis and nuclear magnetic resonance (NMR) are increasingly gaining traction around the world.